News Highlights: Top Company News of the Day
September 19 2018 - 9:30PM
Dow Jones News
Bank of America Corporate, Investment Banking Chief to Depart
Bank of America Corp. corporate and investment banking head
Christian Meissner is leaving the bank, according to an internal
memo reviewed by The Wall Street Journal.
Profit Repatriation Slows in the Second Quarter After Tax Overhaul
U.S. companies repatriated $169.5 billion in foreign profits
between April and June-more than in most recent periods, but
underscoring a cautious approach to shifting huge sums across
borders.
Bank of America to Pay $30 Million in Benchmark-Manipulation Settlement
Bank of America will pay $30 million as part of a settlement
with the CFTC related to charges it tried to manipulate a benchmark
for interest-rate products.
Biggest U.S. Public Pension Looks to China for New Investment Chief
An official with China's foreign-exchange regulator is the lead
candidate to become next investment chief of the largest U.S.
public pension fund.
EU Starts Preliminary Probe of Amazon's Treatment of Merchants
European Union antitrust authorities have opened a preliminary
investigation into Amazon.com's treatment of other merchants that
sell products using its platform, starting a new regulatory front
against an American tech giant.
Goldman Sachs Nears Deal to Spin Off 'Simon' App
Goldman Sachs is nearing a deal to spin off its three-year-old
app that sells complex investment products, the bank's latest bid
to profit from its internal technology.
BuzzFeed Cuts Podcast Team
BuzzFeed News is putting its podcasting ambitions on pause.
Apple's New Strategy: Sell Pricier iPhones First
For the second straight year, Apple is starting to sell its new
iPhone models at different times-but this time, the lag reflects a
staggered production timeline set by the tech giant rather than
manufacturing issues it experienced last year.
Deutsche Bank Senior Banker Advised Bosses to Consider Breakup
A former senior investment banker at Deutsche Bank recommended
earlier this year that the troubled German lender consider breaking
itself up to address its persistent competitive weaknesses.
Novartis' CAR-T Drug Hits First Setback in Europe
Novartis' immunotherapy Kymriah is too expensive to be
recommended for use in adults with B-cell lymphoma that have
relapsed or haven't responded to first-line treatment, a U.K.
regulator said.
(END) Dow Jones Newswires
September 19, 2018 21:15 ET (01:15 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.